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Labeled
• rheumatoid arthritis
Off-Label 
• coronavirus disease 2019 (COVID-19) † • severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection 
†
† Off-label indication
For the treatment of moderately to severely active rheumatoid arthritis in 
patients who have had an inadequate response to 1 or more tumor 
necrosis factor (TNF) antagonists
Oral dosage
• Adults
2 mg PO once daily. May give with or without methotrexate or other non-biologic
(conventional) disease-modifying antirheumatic drugs (DMARDs). Coadministration of
certain drugs may need to be avoided or dosage adjustments may be necessary; review
drug interactions. Use in combination with other Janus kinase (JAK) inhibitors, biologic or
targeted DMARDs, or potent immunosuppressants such as azathioprine and cyclosporine
is not recommended.[63229]
INVESTIGATIONAL USE: For adjunctive use in the treatment of severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection†, the 
virus that causes coronavirus disease 2019 (COVID-19)†
Oral dosage
• Adults
Efficacy has not been established. Due to broad immunosuppressive effects, the National
Institutes of Health (NIH) COVID-19 treatment guidelines recommend against the use of
JAK inhibitors outside of clinical trials.[65314] Doses of 2 mg PO once daily for 10 to 14
days and 4 mg PO daily for 7 to 14 days are being evaluated in combination with antiviral
therapy.[65192] [65205] [65253] [65254] [65346]
Therapeutic Drug Monitoring
Anemia
Determine hemoglobin concentration before baricitinib initiation, and do not start the drug in 
patients with a hemoglobin less than 8 grams/dL. Monitor the hemoglobin concentration 
according to routine patient management. For a hemoglobin concentration less than 8 grams/dL, 
interrupt baricitinib receipt until hemoglobin concentration is 8 grams/dL or more.[63229]
Lymphopenia
Determine absolute lymphocyte count (ALC) before baricitinib initiation, and do not start the drug 
in patients with an ALC less than 500 cells/mm3. Monitor the ALC according to routine patient 
management. For an ALC less than 500 cells/mm3, interrupt baricitinib receipt until ALC is 500 
cells/mm3 or more.[63229]
Neutropenia
Determine absolute neutrophil count (ANC) before baricitinib initiation, and do not start the drug 
in patients with an ANC less than 1,000 cells/mm3. Monitor the ANC according to routine patient 
management. For an ANC less than 1,000 cells/mm3, interrupt baricitinib receipt until ANC is 
1,000 cells/mm3 or more.[63229]
Serious Infection
Avoid use in patients with active, serious infection, including localized infections. If a serious 
infection occurs during treatment, hold baricitinib until the infection is controlled.[63229]
Lipid Elevations
Assess lipid profile approximately 12 weeks after initiation of baricitinib therapy. If elevations 
occur, manage patients according to clinical guidelines.[63229]
Maximum Dosage Limits
• Adults
2 mg/day PO.
• Geriatric
2 mg/day PO.
• Adolescents
Safety and efficacy have not been established.
• Children
Safety and efficacy have not been established.
• Infants
Safety and efficacy have not been established.
• Neonates
Safety and efficacy have not been established.
Patients with Hepatic Impairment Dosing
Mild or moderate impairment: No dosage adjustments needed.
Severe impairment: Not recommended.[63229]
Patients with Renal Impairment Dosing
eGFR more than 60 mL/minute/1.73 m2: No dosage adjustment is needed.
eGFR 30 to 60 mL/minute/1.73 m2: Reduce to 1 mg PO once daily.
eGFR less than 30 mL/minute/1.73 m2: Use not recommended.[63229]
† Off-label indication
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How Supplied
Baricitinib Oral tablet
Olumiant 1mg Tablet (00002-4732) (Eli Lilly and Co) 
Olumiant 2mg Tablet (00002-4182) (Eli Lilly and Co) 
Description/Classification
Description
Baricitinib is an oral Janus kinase (JAK) inhibitor and is considered a targeted synthetic disease-
modifying antirheumatic drug (tsDMARD). Janus kinases are intracellular enzymes that transmit 
signals arising from cytokine interactions on the cellular membrane to influence cellular processes 
of immune cell function. JAK inhibitors have been shown useful for a variety of inflammatory 
conditions. Baricitinib is indicated for adults with moderately to severely active rheumatoid 
arthritis (RA) who have had an inadequate response or intolerance to 1 or more tumor necrosis 
factor (TNF) inhibitors. For patients with rheumatoid arthritis (RA), baricitinib is used as 
monotherapy or in combination with methotrexate or other non-biologic disease-modifying 
antirheumatic drugs (DMARDs). Baricitinib improves RA symptoms and inhibits the radiographic 
progression of structural joint damage.[63229] Guidelines for RA were published before the 
availability of baricitinib, but the drug, like other tsDMARDs, is usually reserved for patients with 
contraindications, intolerance, or inadequate response to biologic agents such as the TNF 
inhibitors. The ideal combination of therapy for individual patients with inflammatory arthritis 
conditions such as RA is determined by treat to target strategies and severity of the disease.[56233]
The use of baricitinib does present some safety concerns. Serious infections and malignancy may 
be precipitated by JAK inhibitors; the drug is not to be used in combination with other JAK 
inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and 
cyclosporine. Also, JAK inhibitors have been associated with an increased risk of thrombosis.
[63229]
Updates for coronavirus disease 2019 (COVID-19):
Based on preliminary data from a study of another immunomodulator (an IL-6 receptor antibody), 
studies have begun to evaluate the use of JAK inhibitors (including baricitinib) for the treatment 
of COVID-19.[65192][65205][65253][65254][65346] However, due to the broad immunosuppressive 
effect, the National Institutes of Health (NIH) COVID-19 treatment guidelines recommend against 
the use of JAK inhibitors outside of clinical trials.[65314]
Classifications
• Musculo-Skeletal System
◦ Antiinflammatory Agents and Antirheumatic Agents
◾ Specific Anti-Rheumatic Agents
◾ Other Specific Antirheumatics
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Administration Information
General Administration Information
For storage information, see the specific product information within the How Supplied section.
Route-Specific Administration
Oral Administration
Oral Solid Formulations
• Administer tablets with or without food.[63229]
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Adverse Reactions
• abdominal pain
• acne vulgaris
• anemia
• candidiasis
• elevated hepatic enzymes
• GI perforation
• hepatotoxicity
• hypercholesterolemia
• hypertriglyceridemia
• infection
• laryngitis
• lymphoma
• lymphopenia
• nausea
• neutropenia
• new primary malignancy
• pharyngitis
• pulmonary embolism
• rhinitis
• sinusitis
• skin cancer
• thrombocytosis
• thromboembolism
• thrombosis
• tracheitis
Serious and sometimes fatal bacterial infection, mycobacterial infection, invasive fungal infection, 
viral infection, or infections due to other opportunistic pathogens have been reported in patients 
receiving baricitinib. The most commonly reported adverse reactions during baricitinib clinical 
trials for rheumatoid arthritis were upper respiratory tract infections (16.3% vs. 11.7% placebo). 
Included in upper respiratory tract infections were acute sinusitis, sinusitis, acute tonsillitis, 
tonsillitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, 
pharyngotonsillitis, rhinitis, sinobronchitis, and tracheitis. During the 16-week treatment period, 
overall infections were reported in 139 patients (99.1 events per 100 patient-years) treated with 
baricitinib 2 mg compared to 253 patients (82.1 events per 100 patient-years) receiving placebo. 
During 0 to 52-week exposure, infections were reported in 200 patients (59.6 events per 100 
patient-years) receiving baricitinib 2 mg. During the 0 to 52 week exposure, the most commonly 
reported infections included viral upper respiratory infection, upper respiratory tract infection, 
urinary tract infection, and bronchitis. During the 16-week treatment period, serious infections 
were reported in 5 patients (3.6 events per 100 patient-years) receiving baricitinib 2 mg and in 13 
patients (4.2 events per 100 patient-years) receiving placebo. During the 0 to 52 week exposure, 
serious infection was reported in 14 patients (4.2 events per 100 patient-years) receiving 
baricitinib 2 mg. The most common serious infections reported with baricitinib included 
pneumonia, herpes zoster, and urinary tract infections. Among opportunistic infections, 
tuberculosis, cryptococcosis, acute histoplasmosis, esophageal candidiasis, pneumocystosis, 
multidermatomal herpes zoster, cytomegalovirus infections, and BK virus were reported with 
baricitinib. During the 0 to 16 week treatment period, an opportunistic infection was reported in 2 
placebo patients (0.6 events per 100 patient-years), no patients taking baricitinib 2 mg, and two 
patients taking baricitinib 4 mg (0.7 events per 100 patient-years); baricitinib 4 mg is not an FDA-
approved dose. In the 0 to 52 week treatment period, opportunistic infections were reported in 1 
patient (0.1 events per 100 patient-years) and 5 patients (0.6 per 100 patient-years) with baricitinib 
2 mg and baricitinib 4 mg, respectively. Viral reactivation, including cases of herpes infection 
reactivation (e.g., herpes zoster), were observed in clinical studies. Herpes simplex and herpes 
zoster were reported in 0.8% and 1% of patients treated with baricitinib 2 mg, respectively 
compared to 0.7% and 0.4% of those receiving placebo, respectively. Included in herpes simplex 
were eczema herpeticum, genital herpes, ophthalmic herpes simplex, and oral herpes. If a patient 
develops herpes zoster, interrupt baricitinib therapy until the episode resolves. Baricitinib should 
not be administered to patients with active tuberculosis. Patients should be evaluated and tested 
for latent or active TB infection prior to and per applicable guidelines during baricitinib 
administration. There were no reported cases of tuberculosis during the 0 to 16 week treatment 
period. In the 0 to 52 week treatment period, tuberculosis was reported in 1 patient taking 
baricitinib 4 mg and 0 patients on baricitinib 2 mg. Cases of disseminated tuberculosis also were 
reported. Some patients have presented with disseminated rather than localized infection and were 
often taking concomitant immunosuppression agents such as methotrexate or corticosteroid 
therapy. Patients should be closely monitored for the development of signs and symptoms of 
infection during and after baricitinib treatment. Interrupt therapy with baricitinib if a patient 
develops a serious infection, an opportunistic infection, or sepsis. A patient who develops a new 
infection during treatment with baricitinib should undergo prompt and complete diagnostic testing 
appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be 
initiated, and the patient should be closely monitored.[63229]
Hematologic laboratory abnormalities have been reported during baricitinib clinical trials. 
Neutropenia, defined as an absolute neutrophil count (ANC) below 1,000 cells/mm3, was reported 
in 0.6% of patients receiving baricitinib 2 mg daily (none reported with placebo). ANC counts 
below 500 cells/mm3 were not reported in any treatment group. Avoid or interrupt baricitinib 
treatment in patients with an ANC less than 1,000 cells/mm3. Anemia, defined as hemoglobin less 
than 8 grams/dL, was reported during baricitinib clinical trials. Avoid or interrupt treatment in 
patients with a hemoglobin less than 8 grams/dL. Lymphopenia, defined as absolute lymphocyte 
count (ALC) less than 500 cells/mm3 was reported during baricitinib clinical trials. Lymphocyte 
counts less than the lower limit of normal were associated with infection in patients treated with 
baricitinib but not in those receiving placebo. Avoid or interrupt baricitinib treatment in patients 
with an ALC less than 500 cells/mm3. Increases in platelet counts (thrombocytosis) above 600,000 
cells/mm3 were reported in 1.1% of patients receiving 2 mg/day baricitinib and 1.1% in those 
receiving placebo. After 16 weeks of treatment, the mean platelet count increased by 3,000 
cells/mm3 in patients receiving placebo and by 15,000 cells/mm3 in patients treated with 
baricitinib 2 mg.[63229]
Serious and even fatal venous thromboembolism, including deep venous thrombosis (DVT) and 
pulmonary embolism (PE), have been reported during baricitinib clinical trials. During the 16-
week treatment period, DVT or PE was reported in 5 patients (1.7 events per 100 patient-years) 
receiving 4 mg daily (not an FDA approved dose); DVT or PE was not reported in those receiving 
placebo or 2 mg daily. Arterial thrombosis during the 16 week treatment period was reported in 1 
patient receiving placebo (0.3 events per 100 patient-years), 2 patients receiving baricitinib 2 mg 
(1.4 events per 100 patient-years) and 2 patients (0.7 events per 100 patient-years) receiving 
baricitinib 4 mg per day. During the 0 to 52 week treatment period, venous thromboses were 
reported in 2 patients (0.6 events per 100 patient-years) receiving 2 mg per day and 7 patients (0.8 
events per 100 patient-years) receiving 4 mg per day. Arterial thromboses were reported in 3 
patients (0.9 events per 100 patient-years) receiving baricitinib 2 mg/day and 3 patients (0.3 events 
per 100 patient-years) receiving 4 mg/day. Baricitinib may cause increases in platelet counts 
(thrombocytosis). There is no clear relationship between platelet count elevations and thrombotic 
events. If signs and symptoms of DVT, PE, or arterial thrombosis occur, promptly evaluate and 
treat patients.[63229]
During baricitinib clinical trials, nausea was reported in 2.7% of patients receiving baricitinib 2 
mg and at rates greater than with placebo. Gastrointestinal (GI) serious reactions, such as GI 
perforation, have been noted among baricitinib recipients, although the role of the drug in these 
events is unknown. Promptly evaluate patients presenting with new-onset abdominal symptoms, 
such as abdominal pain, for early identification of GI perforation. Cautious use of baricitinib is 
advised for patients who may be at increased risk for GI perforation.[63229]
Elevated hepatic enzymes have been reported in clinical trials with the use of baricitinib. Among 
patients receiving baricitinib 2 mg during a 16-week treatment period, alanine aminotransferase 
(ALT) elevations 3 times the upper limit of normal (ULN) or greater occurred in 1.7% of patients 
(vs. 1% placebo) and aspartate aminotransferase (AST) elevations 3 times the ULN or greater 
were reported in 1.3% of patients (vs. 0.8% placebo). Increases 5-times the ULN or more and 10-
times the ULN or more were observed for both ALT and AST in patients in clinical trials. Prompt 
investigation of the cause of hepatic enzyme elevation is recommended to identify potential cases 
of drug-induced liver injury. If increases are observed and drug-induced hepatotoxicity is 
suspected, interrupt baricitinib treatment until this diagnosis is excluded.[63229]
During baricitinib clinical trials, dose-related increases in lipid parameters were reported. 
Elevations were observed at 12 weeks and remained stable thereafter. In patients treated with 
baricitinib 2 mg for 12 weeks, mean LDL cholesterol, mean HDL cholesterol, and mean 
triglycerides increased by 8 mg/dL, 7 mg/dL, and 7 mg/dL, respectively. The mean LDL/HDL 
ratio remained stable. Manage patients according to clinical guidelines for the management of 
hyperlipidemia, hypercholesterolemia or hypertriglyceridemia as per standards of care. Other 
laboratory alterations have been reported. Baricitinib treatment was associated with increases in 
creatine phosphokinase (CPK) within one week of starting the drug, but the CPK elevation leveled 
off after 8 to 12 weeks. At 16 weeks, the mean change in CPK for baricitinib 2 mg/day was 37 
International Units/L. In controlled clinical trials, dose-related increases in serum creatinine (SCr) 
were also observed; at 52 weeks, the mean increase in SCr was less than 0.1 mg/dL with 
baricitinib 4 mg (non-FDA-approved dose). The clinical significance of the observed SCr 
increases is unknown.[63229]
Acne vulgaris was reported in less than 1% of patients receiving baricitinib during clinical trials.
[63229]
Baricitinib may cause a new primary malignancy; malignancies were reported during clinical 
trials. During the 16-week treatment period, 1 patient (0.7 events per 100 patient-years) receiving 
baricitinib 2 mg per day developed a malignancy other than non-melanoma skin cancer (NMSC); 
no events were reported in the placebo group. Lymphoma and other cancers have been observed in 
patients taking baricitinib. During the 0 to 52 week treatment period, malignancies other than 
NMSC were reported in 2 patients (0.6 events per 100 patient-years) receiving baricitinib 2 mg per 
day. NMSC has also been reported in patients treated with baricitinib. Periodic skin evaluations 
are recommended for patients at an increased risk of skin cancer. Consider the risks and benefits 
of baricitinib when considering the continuation of the drug in patients who develop a malignancy.
[63229]
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Contraindications/Precautions
Absolute contraindications are italicized.
• anemia 
• breast-feeding 
• children 
• corticosteroid therapy 
• diabetes mellitus 
• diverticulitis 
• fungal infection 
• geriatric 
• GI perforation 
• hepatic disease 
• hepatitis 
• hepatitis C infection 
• herpes infection 
• human immunodeficiency virus (HIV) 
infection 
• hypercholesterolemia 
• hyperlipidemia 
• immunosuppression 
• infants 
• infection B
• lymphoma 
• neutropenia 
• new primary malignancy B
• pregnancy 
• pulmonary disease 
• renal failure 
• renal impairment 
• skin cancer 
• thrombocytosis 
• thromboembolic disease 
• thromboembolism B
• thrombosis 
• tuberculosis 
• vaccination 
• viral infection 
Avoid use of baricitinib in patients with an active, serious infection, including localized infections. 
Serious and sometimes fatal bacterial infection, mycobacterial infection, invasive fungal infection, 
viral infection, or infections due to other opportunistic pathogens have been reported in 
rheumatoid arthritis patients receiving baricitinib. The risks and benefits of treatment should be 
considered prior to initiating baricitinib in patients: 1) with chronic or recurrent infection; 2) who 
have been exposed to tuberculosis; 3) with a history of a serious or an opportunistic infection; 4) 
who have resided or traveled in areas of endemic tuberculosis or endemic mycoses; or 5) with 
underlying conditions that may predispose them to infection (e.g., diabetes mellitus, human 
immunodeficiency virus (HIV) infection, chronic pulmonary disease, low lymphocyte counts, and 
pre-existing immunosuppression). The most common serious infections reported with baricitinib 
included pneumonia, herpes zoster, and urinary tract infections. Among opportunistic infections, 
tuberculosis, cryptococcosis, acute histoplasmosis, esophageal candidiasis, pneumocystosis, 
multidermatomal herpes zoster, cytomegalovirus infections, and BK virus were reported with 
baricitinib. Some patients have presented with disseminated rather than localized disease, and 
were often taking concomitant immunosuppression agents such as methotrexate or corticosteroid 
therapy. Ask patients if they have lived or have traveled to the Ohio and Mississippi River valleys 
or the Southwest because of an increased chance of acquiring certain kinds of fungal infections 
such as histoplasmosis, coccidioidomycosis, or blastomycosis. Viral reactivation, including cases 
of herpes infection reactivation (e.g., herpes zoster), were observed in clinical studies. If a patient 
develops herpes zoster, interrupt baricitinib therapy until the episode resolves. Carefully consider 
the risks and benefits of baricitinib before starting the drug in patients who have been exposed to 
tuberculosis (TB). Baricitinib should not be administered to patients with active tuberculosis. 
Patients should be evaluated and tested for latent or active TB infection prior to and per applicable 
guidelines during baricitinib administration. Consider anti-tuberculosis therapy before baricitinib 
administration in patients with a past history of latent or active tuberculosis in whom an adequate 
course of treatment cannot be confirmed and for patients with a negative test for latent 
tuberculosis but who have risk factors for tuberculosis infection. Consultation with a physician 
with expertise in the treatment of tuberculosis is recommended to aid in the decision about 
whether initiating anti-tuberculosis therapy is appropriate for an individual patient. Monitor 
patients for the development of signs and symptoms of tuberculosis in all patients during 
treatment. Patients should be closely monitored for the development of signs and symptoms of 
infection during and after treatment with baricitinib. Therapy with baricitinib should be interrupted 
if a patient develops a serious infection, an opportunistic infection, or sepsis. A patient who 
develops a new infection during treatment with baricitinib should undergo prompt and complete 
diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial 
therapy should be initiated, and the patient should be closely monitored.[63229]
Perform screening for viral hepatitis in accordance with clinical guidelines before starting therapy 
with baricitinib. The impact of baricitinib on chronic viral hepatitis reactivation is unknown. 
Patients with evidence of active hepatitis B or hepatitis C infection were excluded from clinical 
trials. Patients who were positive for hepatitis C antibody but negative for hepatitis C virus RNA 
were permitted to enroll. Patients with positive hepatitis B surface antibody and hepatitis B core 
antibody, without hepatitis B surface antigen, were permitted to enroll; such patients should be 
monitored for expression of hepatitis B virus (HBV) DNA. Should HBV DNA be detected, 
consult with a hepatologist. Use baricitinib with caution in any other patient with hepatic disease
or impairment. Baricitinib is not recommended for patients with severe hepatic impairment. 
Increases in liver enzymes of 5 times and up to 10 times the upper limit of normal (ULN) were 
reported for both ALT and AST in clinical trials. Liver function tests (LFTs) should be evaluated at 
baseline and thereafter according to routine patient management. If increases in ALT or AST are 
seen and drug-induced liver toxicity is suspected, interrupt baricitinib treatment until drug-induced 
toxicity is excluded.[63229]
Determine neutrophil and lymphocyte counts before baricitinib initiation. Do not start the drug in 
patients with an absolute lymphocyte count (ALC) less than 500 cells/mm3 or in patients with 
absolute neutrophil count (ANC) less than 1,000 cells/mm3. Baricitinib may cause lymphopenia 
and neutropenia. Monitor the ANC and ALC periodically during baricitinib treatment according to 
routine patient management. Interrupt treatment in patients with an ANC less than 1,000 
cells/mm3 or an ALC less than 500 cells/mm3 until the counts have recovered to amounts equal to 
or above these thresholds.[63229]
Determine the hemoglobin concentration before baricitinib initiation, and do not start the drug in 
patients with anemia defined as hemoglobin less than 8 grams/dL. Baricitinib may cause anemia. 
For patients who have hemoglobin 8 grams/dL or greater, monitor the hemoglobin concentration 
according to routine patient management. Treatment with baricitinib should be interrupted in 
patients who develop hemoglobin levels less than 8 grams/dL until the hemoglobin has recovered 
to 8 grams/dL or higher.[63229]
Baricitinib may increase the risk for a new primary malignancy. Consider the risks and benefits of 
baricitinib prior to initiating therapy in patients with a known cancer other than a successfully 
treated non-melanoma skin cancer (NMSC) or when considering continuing the drug in patients 
who develop a malignancy. Lymphoma and other cancers have also been observed in patients 
taking baricitinib. NMSCs have also been reported in patients treated with baricitinib. Periodic 
skin examination is recommended for patients who are at increased risk for skin cancer.[63229]
Use baricitinib with caution in patients with thromboembolic disease or who are at an increased 
risk of thromboembolism. Serious and even fatal venous thromboembolism, including deep 
venous thrombosis (DVT) and pulmonary embolism (PE), have been reported at an increased rate 
in patients treated with baricitinib compared to placebo. In addition, arterial thrombosis events in 
the extremities have been reported in clinical studies; many of these adverse events were serious 
and some resulted in death. Baricitinib may cause increases in platelet counts (thrombocytosis). 
There is no clear relationship between platelet count elevations and thrombotic events. If signs and 
symptoms of DVT, PE, or arterial thrombosis occur, promptly evaluate and treat patients.[63229]
Use baricitinib with caution in patients with renal impairment. Dosage reductions are 
recommended in patients with an estimated glomerular filtration rate (eGFR) of 30 to 60 
mL/minute/1.73 m2. Baricitinib is not recommended in patients with renal failure or an eGFR less 
than 30 mL/minute/1.73 m2.[63229]
Update immunizations in agreement with current immunization guidelines prior to initiating 
baricitinib therapy. Patients who are taking baricitinib should not receive vaccination with live 
vaccines. These patients may receive non-live vaccines during baricitinib therapy. The interval 
between live vaccinations and the initiation of baricitinib therapy should be in accordance with 
current vaccination guidelines regarding immunosuppressive agents.[63229]
Cautious use of baricitinib is advised for patients who may be at increased risk for gastrointestinal 
(GI) perforation (e.g., patients with a history of diverticulitis). GI perforation has been noted 
among baricitinib recipients, although the role of baricitinib in these events is not known. Patients 
presenting with new onset abdominal symptoms should be evaluated promptly for early 
identification of GI perforation.[63229]
Use baricitinib with caution in patients with hyperlipidemia or hypercholesterolemia. Treatment 
with baricitinib was associated with increases in lipid parameters including total cholesterol, low-
density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. 
Assessment of lipid parameters in all patients should be performed approximately 12 weeks 
following initiation of baricitinib therapy. Manage patients according to clinical guidelines for the 
management of hyperlipidemia.[63229]
During clinical trials, no overall differences in safety or effectiveness were noted between geriatric
and younger adult patients receiving baricitinib. However, greater sensitivity of some older 
individuals cannot be ruled out. Baricitinib is extensively excreted by the kidney, and the risk of 
adverse reactions may be greater for patients with impaired renal function. Geriatric patients are 
more likely to have decreased renal function; therefore, cautious dose selection and monitoring of 
renal function may be warranted in geriatric patients.[63229]
Sufficient data are not available to inform a drug-associated risk for major birth defects or 
miscarriage with the use of baricitinib during human pregnancy. In embryofetal animal studies, 
oral administration to rats and rabbits at exposures greater than 20 and 84 times the maximum 
recommended human dose (MRHD), respectively, resulted in reduced fetal body weights, 
increased embryolethality (rabbits only), and dose-related increases in skeletal malformations. 
Developmental toxicity was not observed in pregnant rats and rabbits treated with baricitinib at 
approximately 5 and 13 times the MRHD, respectively. In a pre- and post-development study in 
pregnant rats, oral baricitinib administration at exposures approximately 43 times the MRHD 
resulted in a reduction in pup viability, decreased fetal birth weight, reduced fetal body weight 
gain, decreased cytotoxic T cells on post-natal day 35 with no evidence of recovery by day 65, and 
developmental delays that might be attributable to decreased body weight gain. No developmental 
toxicity was observed at exposures approximately 9 times the MRHD.[63229]
Because of the potential for serious adverse reactions in a nursing infant, breast-feeding during 
baricitinib therapy is not recommended. No data are available on the presence of baricitinib in 
human milk, the effects of the drug on the breast-fed infant, or the effects on milk production. 
Baricitinib is present in the milk of lactating rats; the clinical relevance of this to human lactation 
is not known.[63229] Etanercept and infliximab may be potential alternatives to consider during 
breast-feeding. However, assessment of indication and patient-specific factors should be 
performed before considering an alternative agent.[61808] [62180]
The safety and efficacy of baricitinib in infants, children, and adolescents under the age of 18 
years have not been established.[63229]
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Mechanism of Action
Baricitinib is an oral Janus kinase (JAK) inhibitor. Janus kinases are intracellular enzymes that 
transmit signals arising from cytokine or growth factor receptor interactions on the cellular 
membrane to influence cellular processes of immune cell function and hematopoiesis. JAK-
mediated signaling is pivotal in immune activation, as cytokine receptors are expressed on most 
immune cells. Within the signaling pathway, JAKs phosphorylate and activate signal transducers 
and activators of transcription proteins (STATs), which modulate intracellular activity including 
gene expression. Baricitinib modulates the signaling pathway at the point of JAKs, preventing the 
phosphorylation and activation of STATs. Cytokine signaling is transmitted through pairing of 
JAKs such as JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, and JAK2/TYK2. Baricitinib 
has greater affinity for JAK1, JAK2, and TYK2, relative to JAK3. In human leukocytes, 
baricitinib inhibits cytokine-induced STAT phosphorylation mediated by JAK1/JAK2, 
JAK1/JAK3, JAK1/TYK2, or JAK2/TYK2 with comparable potencies. However, the relevance of 
specific JAK combinations to therapeutic effectiveness is not known.[63229]
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Pharmacokinetics
Baricitinib is administered orally. After intravenous administration, the volume of distribution is 
76 L, indicating the distribution of baricitinib into tissues. Plasma and serum protein bindings are 
approximately 50% and 45%, respectively. Approximately 6% of the orally administered 
baricitinib dose is identified as metabolites (3 from urine and 1 from feces), with CYP3A4 
identified as the main metabolizing enzyme. No metabolites of baricitinib were quantifiable in 
plasma. In a clinical pharmacology study, approximately 75% of the administered dose was 
eliminated in the urine, while about 20% of the dose was eliminated in the feces. Baricitinib is 
predominately excreted as unchanged drug in the urine (69%) and feces (15%). The elimination 
half-life is approximately 12 hours in patients with rheumatoid arthritis (RA).[63229]
Affected cytochrome P450 (CYP450) isoenzymes and drug transporters: CYP3A4, OAT3, P-
glycoprotein (P-gp), BCRP, and MATE2-K
In vitro studies indicate that baricitinib is a substrate of CYP3A4, OAT3, P-gp, BCRP, and 
MATE2-K. In clinical pharmacology studies, coadministration with ketoconazole (a strong 
CYP3A4) did not have an effect on the pharmacokinetics of baricitinib. In addition, no clinically 
meaningful effects on baricitinib pharmacokinetics when it was coadministered with fluconazole 
(CYP3A/CYP2C19/CYP2C9 inhibitor) or rifampin (a strong CYP3A4 inducer). Coadministration 
with probenecid (a strong OAT3 inhibitor) resulted in an approximately 2-fold increase in 
baricitinib exposure. Coadministration with OAT3 inhibitors with less inhibition potential (i.e., 
ibuprofen and diclofenac) had minimal effect on baricitinib exposure. No clinically meaningful 
effect on the pharmacokinetics of baricitinib was noted with the coadministration of cyclosporine 
(a P-gp and BCRP inhibitor). In vitro data indicate baricitinib inhibits OAT1, OAT2, OAT3, 
OCT1, OCT2, OAT1B3, BCRP, and MATE1 and MATE2-K, but clinically meaningful changes in 
the pharmacokinetics of drugs that are substrates for these transporters are unlikely.[63229]
Route-Specific Pharmacokinetics
• Oral Route
The absolute oral bioavailability of baricitinib is approximately 80%. In clinical trials, 
baricitinib was administered without regard to meals. Administration with meals is not 
associated with a clinically relevant effect on exposure. Peak plasma concentrations of 
baricitinib after oral administration were reached within 1 hour, and a dose-
proportional increase in systemic exposure was observed in the therapeutic dose range. 
Steady-state concentrations are achieved in 2 to 3 days with negligible accumulation.
[63229]
Special Populations
• Hepatic Impairment
The systemic exposure and maximum concentration of baricitinib is increased by 1.19- 
and 1.08-fold for patients with moderate hepatic impairment compared to those with 
normal hepatic function; however, no dosage adjustment is recommended for mild or 
moderate hepatic impairment. Baricitinib is not recommended in patients with severe 
hepatic impairment due to a lack of data.[63229]
• Renal Impairment
The systemic exposure (AUC) of baricitinib was increased by 1.41-, 2.22-, 4.05-, and 
2.41-fold for mild, moderate, severe, and end-stage renal disease (ESRD with 
hemodialysis) renal impairment groups compared to subjects with normal renal 
function. The maximum concentration (Cmax) increased by 1.16-, 1.46-, 1.40- and 
0.88-fold for mild, moderate, severe, and ESRD patients, respectively, compared to 
patients with normal renal function. Dosage reduction is recommended for patients 
with moderate renal impairment (estimated GFR of 30 to 60 mL/minute/1.73 m2). 
Baricitinib is not recommended for use in patients with severe renal impairment 
(estimated GFR of less than 30 mL/minute/1.73 m2).[63229]
• Pediatrics
There are no pediatric data regarding the pharmacokinetics of baricitinib.[63229]
• Geriatric
Age did not have a clinically relevant effect on the pharmacokinetic profile of 
baricitinib.[63229]
• Gender Differences
Gender did not have a clinically relevant effect on the pharmacokinetic profile of 
baricitinib.[63229]
• Ethnic Differences
Ethnic differences did not have a clinically relevant effect on the pharmacokinetic 
profile of baricitinib.[63229]
• Obesity
Body weight did not have a clinically relevant effect on the pharmacokinetic profile of 
baricitinib.[63229]
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Pregnancy/Breast-feeding
Pregnancy
Sufficient data are not available to inform a drug-associated risk for major birth defects or 
miscarriage with the use of baricitinib during human pregnancy. In embryofetal animal studies, 
oral administration to rats and rabbits at exposures greater than 20 and 84 times the maximum 
recommended human dose (MRHD), respectively, resulted in reduced fetal body weights, 
increased embryolethality (rabbits only), and dose-related increases in skeletal malformations. 
Developmental toxicity was not observed in pregnant rats and rabbits treated with baricitinib at 
approximately 5 and 13 times the MRHD, respectively. In a pre- and post-development study in 
pregnant rats, oral baricitinib administration at exposures approximately 43 times the MRHD 
resulted in a reduction in pup viability, decreased fetal birth weight, reduced fetal body weight 
gain, decreased cytotoxic T cells on post-natal day 35 with no evidence of recovery by day 65, and 
developmental delays that might be attributable to decreased body weight gain. No developmental 
toxicity was observed at exposures approximately 9 times the MRHD.[63229]
Breast-Feeding
Because of the potential for serious adverse reactions in a nursing infant, breast-feeding during 
baricitinib therapy is not recommended. No data are available on the presence of baricitinib in 
human milk, the effects of the drug on the breast-fed infant, or the effects on milk production. 
Baricitinib is present in the milk of lactating rats; the clinical relevance of this to human lactation 
is not known.[63229] Etanercept and infliximab may be potential alternatives to consider during 
breast-feeding. However, assessment of indication and patient-specific factors should be 
performed before considering an alternative agent.[61808] [62180]
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Interactions
Level 2 (Major)
• Abatacept
• Adalimumab
• Anakinra
• Azathioprine
• Bacillus Calmette-Guerin Vaccine, BCG
• Canakinumab
• Certolizumab pegol
• Colchicine; Probenecid
• Cyclosporine
• Etanercept
• Golimumab
• Infliximab
• Influenza Virus Vaccine
• Intranasal Influenza Vaccine
• Live Vaccines
• Measles Virus; Mumps Virus; Rubella 
Virus; Varicella Virus Vaccine, Live
• Measles/Mumps/Rubella Vaccines, 
MMR
• Probenecid
• Rituximab
• Rituximab; Hyaluronidase
• Rotavirus Vaccine
• Rubella Virus Vaccine Live
• Sarilumab
• Secukinumab
• Smallpox and Monkeypox Vaccine, 
Live, Nonreplicating
• Smallpox Vaccine, Vaccinia Vaccine
• Tocilizumab
• Tofacitinib
• Tumor Necrosis Factor modifiers
• Typhoid Vaccine
• Upadacitinib
• Ustekinumab
• Varicella-Zoster Virus Vaccine, Live
• Yellow Fever Vaccine, Live
Level 3 (Moderate)
• Leflunomide • Teriflunomide
Abatacept: (Major) Concomitant use of baricitinib with biologic DMARDs, such as abatacept, is 
not recommended because of the possibility of increased immunosuppression and increased 
infection risk. There is insufficient experience to assess the safety and efficacy of this 
combination. Baricitinib may be used as monotherapy or concomitantly with methotrexate or 
other nonbiologic DMARDs. [31761] [63229]
Adalimumab: (Major) Concomitant use of baricitinib with biologic DMARDs, such as tumor 
necrosis factor (TNF) modifiers, is not recommended because of the possibility of increased 
immunosuppression and increased infection risk. Baricitinib may be used as monotherapy or 
concomitantly with methotrexate or other nonbiologic DMARDs. [63229]
Anakinra: (Major) Concomitant use of baricitinib with biologic DMARDs, such as anakinra, is not 
recommended because of the possibility of increased immunosuppression and increased infection 
risk. Baricitinib may be used as monotherapy or concomitantly with methotrexate or other 
nonbiologic DMARDs. [63229]
Azathioprine: (Major) Do not use baricitinib in combination with potent immunosuppressants 
such as azathioprine. A risk of added immunosuppression exists when baricitinib is 
coadministered with potent immunosuppressives. Combined use of multiple-dose baricitinib with 
potent immunosuppressives has not been studied in patients with rheumatoid arthritis. [63229]
Bacillus Calmette-Guerin Vaccine, BCG: (Major) Do not administer live virus vaccines to patients 
taking baricitinib, as no data are available on the secondary transmission of infection by live 
vaccines. Also, no data are available on the response to vaccination with any vaccine during 
baricitinib receipt. Before baricitinib initiation, review the vaccination status of patients, and 
update immunizations in agreement with current immunization guidelines. [63229]
Canakinumab: (Major) Concomitant use of baricitinib with biologic DMARDs, such as 
canakinumab, is not recommended because of the possibility of increased immunosuppression and 
increased infection risk. [63229]
Certolizumab pegol: (Major) Concomitant use of baricitinib with biologic DMARDs, such as 
tumor necrosis factor (TNF) modifiers, is not recommended because of the possibility of increased 
immunosuppression and increased infection risk. Baricitinib may be used as monotherapy or 
concomitantly with methotrexate or other nonbiologic DMARDs. [63229]
Colchicine; Probenecid: (Major) Reduce the dose of baricitinib to 1 mg/day PO in patients 
receiving concomitant therapy with probenecid. Coadministration of baricitinib and probenecid 
may result in increased baricitinib exposure. Baricitinib is an OAT3 substrate and probenecid is a 
strong OAT3 inhibitor. In a drug interaction study, administration of probenecid increased 
baricitinib exposure by 2-fold. [63229]
Cyclosporine: (Major) Do not use baricitinib in combination with potent immunosuppressants 
such as cyclosporine. A risk of added immunosuppression exists when baricitinib is 
coadministered with potent immunosuppressives. [63229]
Etanercept: (Major) Concomitant use of baricitinib with biologic DMARDs, such as tumor 
necrosis factor (TNF) modifiers, is not recommended because of the possibility of increased 
immunosuppression and increased infection risk. Baricitinib may be used as monotherapy or 
concomitantly with methotrexate or other nonbiologic DMARDs. [63229]
Golimumab: (Major) Concomitant use of baricitinib with biologic DMARDs, such as tumor 
necrosis factor (TNF) modifiers, is not recommended because of the possibility of increased 
immunosuppression and increased infection risk. Baricitinib may be used as monotherapy or 
concomitantly with methotrexate or other nonbiologic DMARDs. [63229]
Infliximab: (Major) Concomitant use of baricitinib with biologic DMARDs, such as tumor 
necrosis factor (TNF) modifiers, is not recommended because of the possibility of increased 
immunosuppression and increased infection risk. Baricitinib may be used as monotherapy or 
concomitantly with methotrexate or other nonbiologic DMARDs. [63229]
Influenza Virus Vaccine: (Major) Do not administer live virus vaccines to patients taking 
baricitinib, as no data are available on the secondary transmission of infection by live vaccines. 
Also, no data are available on the response to vaccination with any vaccine during baricitinib 
receipt. Before baricitinib initiation, review the vaccination status of patients, and update 
immunizations in agreement with current immunization guidelines. [63229]
Intranasal Influenza Vaccine: (Major) Do not administer live virus vaccines to patients taking 
baricitinib, as no data are available on the secondary transmission of infection by live vaccines. 
Also, no data are available on the response to vaccination with any vaccine during baricitinib 
receipt. Before baricitinib initiation, review the vaccination status of patients, and update 
immunizations in agreement with current immunization guidelines. [63229]
Leflunomide: (Moderate) Monitor for increased baricitinib effects if administered with 
leflunomide as baricitinib exposure may increase; a baricitinib dose reduction may be necessary. 
Baricitinib is an OAT3 substrate; leflunomide is an OAT3 inhibitor. [49634] [63229]
Live Vaccines: (Major) Do not administer live virus vaccines to patients taking baricitinib, as no 
data are available on the secondary transmission of infection by live vaccines. Also, no data are 
available on the response to vaccination with any vaccine during baricitinib receipt. Before 
baricitinib initiation, review the vaccination status of patients, and update immunizations in 
agreement with current immunization guidelines. [63229]
Measles Virus; Mumps Virus; Rubella Virus; Varicella Virus Vaccine, Live: (Major) Do not 
administer live virus vaccines to patients taking baricitinib, as no data are available on the 
secondary transmission of infection by live vaccines. Also, no data are available on the response to 
vaccination with any vaccine during baricitinib receipt. Before baricitinib initiation, review the 
vaccination status of patients, and update immunizations in agreement with current immunization 
guidelines. [63229]
Measles/Mumps/Rubella Vaccines, MMR: (Major) Do not administer live virus vaccines to 
patients taking baricitinib, as no data are available on the secondary transmission of infection by 
live vaccines. Also, no data are available on the response to vaccination with any vaccine during 
baricitinib receipt. Before baricitinib initiation, review the vaccination status of patients, and 
update immunizations in agreement with current immunization guidelines. [63229]
Probenecid: (Major) Reduce the dose of baricitinib to 1 mg/day PO in patients receiving 
concomitant therapy with probenecid. Coadministration of baricitinib and probenecid may result 
in increased baricitinib exposure. Baricitinib is an OAT3 substrate and probenecid is a strong 
OAT3 inhibitor. In a drug interaction study, administration of probenecid increased baricitinib 
exposure by 2-fold. [63229]
Rituximab: (Major) Concomitant use of baricitinib with biologic DMARDs, such as rituximab, is 
not recommended because of the possibility of increased immunosuppression and increased 
infection risk. Baricitinib may be used as monotherapy or concomitantly with methotrexate or 
other nonbiologic DMARDs. [63229]
Rituximab; Hyaluronidase: (Major) Concomitant use of baricitinib with biologic DMARDs, such 
as rituximab, is not recommended because of the possibility of increased immunosuppression and 
increased infection risk. Baricitinib may be used as monotherapy or concomitantly with 
methotrexate or other nonbiologic DMARDs. [63229]
Rotavirus Vaccine: (Major) Do not administer live virus vaccines to patients taking baricitinib, as 
no data are available on the secondary transmission of infection by live vaccines. Also, no data are 
available on the response to vaccination with any vaccine during baricitinib receipt. Before 
baricitinib initiation, review the vaccination status of patients, and update immunizations in 
agreement with current immunization guidelines. [63229]
Rubella Virus Vaccine Live: (Major) Do not administer live virus vaccines to patients taking 
baricitinib, as no data are available on the secondary transmission of infection by live vaccines. 
Also, no data are available on the response to vaccination with any vaccine during baricitinib 
receipt. Before baricitinib initiation, review the vaccination status of patients, and update 
immunizations in agreement with current immunization guidelines. [63229]
Sarilumab: (Major) Avoid the concomitant use of sarilumab with other biological DMARDs such 
as baricitinib; coadministration has not been studied and may result in additive 
immunosuppression and increased risk of infection. [61976] [63229]
Secukinumab: (Major) Concomitant use of baricitinib with biologic DMARDs, such as 
secukinumab, is not recommended because of the possibility of increased immunosuppression and 
increased infection risk. Baricitinib may be used as monotherapy or concomitantly with 
methotrexate or other nonbiologic DMARDs. [63229]
Smallpox and Monkeypox Vaccine, Live, Nonreplicating: (Major) Do not administer live virus 
vaccines to patients taking baricitinib, as no data are available on the secondary transmission of 
infection by live vaccines. Also, no data are available on the response to vaccination with any 
vaccine during baricitinib receipt. Before baricitinib initiation, review the vaccination status of 
patients, and update immunizations in agreement with current immunization guidelines. [63229]
Smallpox Vaccine, Vaccinia Vaccine: (Major) Do not administer live virus vaccines to patients 
taking baricitinib, as no data are available on the secondary transmission of infection by live 
vaccines. Also, no data are available on the response to vaccination with any vaccine during 
baricitinib receipt. Before baricitinib initiation, review the vaccination status of patients, and 
update immunizations in agreement with current immunization guidelines. [63229]
Teriflunomide: (Moderate) Monitor for increased baricitinib effects if administered with 
teriflunomide as baricitinib exposure may increase; a baricitinib dose reduction may be necessary. 
Baricitinib is an OAT3 substrate; teriflunomide is an OAT3 inhibitor. [51794] [63229]
Tocilizumab: (Major) Avoid the concomitant use of tocilizumab with other biological DMARDs 
such as baricitinib; coadministration has not been studied and may result in additive 
immunosuppression and increased risk of infection. [38283] [63229]
Tofacitinib: (Major) Concomitant use of baricitinib with tofacitinib is not recommended because 
of the duplication of the mechanism of action (both are Janus kinase inhibitors, also known as 
JAK inhibitors) and the possibility of increased immunosuppression and increased infection risk. 
Both drugs are known to cause elevations in hepatic enzymes and gastrointestinal perforation, and 
a possibility for increased thrombotic risk. [63229]
Tumor Necrosis Factor modifiers: (Major) Concomitant use of baricitinib with biologic 
DMARDs, such as tumor necrosis factor (TNF) modifiers, is not recommended because of the 
possibility of increased immunosuppression and increased infection risk. Baricitinib may be used 
as monotherapy or concomitantly with methotrexate or other nonbiologic DMARDs. [63229]
Typhoid Vaccine: (Major) Do not administer live virus vaccines to patients taking baricitinib, as 
no data are available on the secondary transmission of infection by live vaccines. Also, no data are 
available on the response to vaccination with any vaccine during baricitinib receipt. Before 
baricitinib initiation, review the vaccination status of patients, and update immunizations in 
agreement with current immunization guidelines. [63229]
Upadacitinib: (Major) Concomitant use of baricitinib with upadacitinib is not recommended 
because of the duplication of the mechanism of action (both are Janus kinase inhibitors, also 
known as JAK inhibitors) and the possibility of increased immunosuppression and increased 
infection risk. Both drugs are known to cause elevations in hepatic enzymes and gastrointestinal 
perforation, and a possibility for increased thrombotic risk. [64572]
Ustekinumab: (Major) Concomitant use of baricitinib with biologic DMARDs, such as 
ustekinumab, is not recommended because of the possibility of increased immunosuppression and 
increased infection risk. Baricitinib may be used as monotherapy or concomitantly with 
methotrexate or other nonbiologic DMARDs. [63229]
Varicella-Zoster Virus Vaccine, Live: (Major) Do not administer live virus vaccines to patients 
taking baricitinib, as no data are available on the secondary transmission of infection by live 
vaccines. Also, no data are available on the response to vaccination with any vaccine during 
baricitinib receipt. Before baricitinib initiation, review the vaccination status of patients, and 
update immunizations in agreement with current immunization guidelines. [63229]
Yellow Fever Vaccine, Live: (Major) Do not administer live virus vaccines to patients taking 
baricitinib, as no data are available on the secondary transmission of infection by live vaccines. 
Also, no data are available on the response to vaccination with any vaccine during baricitinib 
receipt. Before baricitinib initiation, review the vaccination status of patients, and update 
immunizations in agreement with current immunization guidelines. [63229]
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Monitoring Parameters
• CBC with differential
• hemoglobin/hematocrit
• LFTs
• serum cholesterol profile
• serum creatinine/BUN
• skin cancer screening exam
• tuberculin skin test
US Drug Names
• OLUMIANT
Global Drug names
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